vs

Side-by-side financial comparison of KADANT INC (KAI) and Protagonist Therapeutics, Inc (PTGX). Click either name above to swap in a different company.

KADANT INC is the larger business by last-quarter revenue ($271.6M vs $170.6M, roughly 1.6× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 10.2%, a 67.0% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs -0.0%). Protagonist Therapeutics, Inc produced more free cash flow last quarter ($182.8M vs $44.1M).

Kadant Inc. is a company that was established in 1991, as a partly privately owned subsidiary of Thermo Electron, and partly publicly traded company, and was fully spun out and renamed Kadant in 2001. The company supports papermaking, paper recycling, wood processing, material handling, and other processing industries. Kadant is a multi-national corporation with operations in Asia, Europe, North America, and South America.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.

KAI vs PTGX — Head-to-Head

Bigger by revenue
KAI
KAI
1.6× larger
KAI
$271.6M
$170.6M
PTGX
Growing faster (revenue YoY)
PTGX
PTGX
+184.4% gap
PTGX
184.4%
-0.0%
KAI
Higher net margin
PTGX
PTGX
67.0% more per $
PTGX
77.2%
10.2%
KAI
More free cash flow
PTGX
PTGX
$138.7M more FCF
PTGX
$182.8M
$44.1M
KAI

Income Statement — Q3 FY2025 vs Q4 FY2024

Metric
KAI
KAI
PTGX
PTGX
Revenue
$271.6M
$170.6M
Net Profit
$27.7M
$131.7M
Gross Margin
45.2%
Operating Margin
15.7%
74.3%
Net Margin
10.2%
77.2%
Revenue YoY
-0.0%
184.4%
Net Profit YoY
-12.2%
381.7%
EPS (diluted)
$2.35
$2.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KAI
KAI
PTGX
PTGX
Q3 25
$271.6M
Q2 25
$255.3M
Q1 25
$239.2M
Q4 24
$258.0M
$170.6M
Q3 24
$271.6M
Q2 24
$274.8M
Q1 24
$249.0M
$255.0M
Q4 23
$238.7M
Net Profit
KAI
KAI
PTGX
PTGX
Q3 25
$27.7M
Q2 25
$26.2M
Q1 25
$24.1M
Q4 24
$24.0M
$131.7M
Q3 24
$31.6M
Q2 24
$31.3M
Q1 24
$24.7M
$207.3M
Q4 23
$27.4M
Gross Margin
KAI
KAI
PTGX
PTGX
Q3 25
45.2%
Q2 25
45.9%
Q1 25
46.1%
Q4 24
43.4%
Q3 24
44.7%
Q2 24
44.4%
Q1 24
44.6%
Q4 23
42.7%
Operating Margin
KAI
KAI
PTGX
PTGX
Q3 25
15.7%
Q2 25
15.4%
Q1 25
14.9%
Q4 24
14.3%
74.3%
Q3 24
18.0%
Q2 24
17.6%
Q1 24
14.8%
80.9%
Q4 23
16.3%
Net Margin
KAI
KAI
PTGX
PTGX
Q3 25
10.2%
Q2 25
10.2%
Q1 25
10.1%
Q4 24
9.3%
77.2%
Q3 24
11.6%
Q2 24
11.4%
Q1 24
9.9%
81.3%
Q4 23
11.5%
EPS (diluted)
KAI
KAI
PTGX
PTGX
Q3 25
$2.35
Q2 25
$2.22
Q1 25
$2.04
Q4 24
$2.04
$2.01
Q3 24
$2.68
Q2 24
$2.66
Q1 24
$2.10
$3.26
Q4 23
$2.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KAI
KAI
PTGX
PTGX
Cash + ST InvestmentsLiquidity on hand
$124.5M
$418.9M
Total DebtLower is stronger
$254.6M
Stockholders' EquityBook value
$949.8M
$675.3M
Total Assets
$1.5B
$744.7M
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KAI
KAI
PTGX
PTGX
Q3 25
$124.5M
Q2 25
$95.3M
Q1 25
$91.7M
Q4 24
$94.7M
$418.9M
Q3 24
$88.4M
Q2 24
$73.8M
Q1 24
$81.4M
$322.6M
Q4 23
$103.8M
Total Debt
KAI
KAI
PTGX
PTGX
Q3 25
$254.6M
Q2 25
$245.7M
Q1 25
$273.5M
Q4 24
$285.2M
Q3 24
$323.2M
Q2 24
$342.0M
Q1 24
$306.8M
Q4 23
$107.7M
Stockholders' Equity
KAI
KAI
PTGX
PTGX
Q3 25
$949.8M
Q2 25
$926.0M
Q1 25
$876.0M
Q4 24
$847.1M
$675.3M
Q3 24
$851.7M
Q2 24
$807.7M
Q1 24
$782.7M
$560.4M
Q4 23
$773.7M
Total Assets
KAI
KAI
PTGX
PTGX
Q3 25
$1.5B
Q2 25
$1.5B
Q1 25
$1.4B
Q4 24
$1.4B
$744.7M
Q3 24
$1.5B
Q2 24
$1.5B
Q1 24
$1.4B
$629.3M
Q4 23
$1.2B
Debt / Equity
KAI
KAI
PTGX
PTGX
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.31×
Q4 24
0.34×
Q3 24
0.38×
Q2 24
0.42×
Q1 24
0.39×
Q4 23
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KAI
KAI
PTGX
PTGX
Operating Cash FlowLast quarter
$47.3M
$184.2M
Free Cash FlowOCF − Capex
$44.1M
$182.8M
FCF MarginFCF / Revenue
16.2%
107.1%
Capex IntensityCapex / Revenue
1.2%
0.8%
Cash ConversionOCF / Net Profit
1.70×
1.40×
TTM Free Cash FlowTrailing 4 quarters
$145.9M
$101.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KAI
KAI
PTGX
PTGX
Q3 25
$47.3M
Q2 25
$40.5M
Q1 25
$22.8M
Q4 24
$51.9M
$184.2M
Q3 24
$52.5M
Q2 24
$28.1M
Q1 24
$22.8M
$-27.4M
Q4 23
$59.2M
Free Cash Flow
KAI
KAI
PTGX
PTGX
Q3 25
$44.1M
Q2 25
$36.5M
Q1 25
$19.0M
Q4 24
$46.3M
$182.8M
Q3 24
$48.3M
Q2 24
$23.1M
Q1 24
$16.6M
$-27.7M
Q4 23
$49.5M
FCF Margin
KAI
KAI
PTGX
PTGX
Q3 25
16.2%
Q2 25
14.3%
Q1 25
7.9%
Q4 24
17.9%
107.1%
Q3 24
17.8%
Q2 24
8.4%
Q1 24
6.7%
-10.9%
Q4 23
20.7%
Capex Intensity
KAI
KAI
PTGX
PTGX
Q3 25
1.2%
Q2 25
1.6%
Q1 25
1.6%
Q4 24
2.2%
0.8%
Q3 24
1.5%
Q2 24
1.8%
Q1 24
2.5%
0.1%
Q4 23
4.1%
Cash Conversion
KAI
KAI
PTGX
PTGX
Q3 25
1.70×
Q2 25
1.55×
Q1 25
0.95×
Q4 24
2.16×
1.40×
Q3 24
1.66×
Q2 24
0.90×
Q1 24
0.92×
-0.13×
Q4 23
2.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KAI
KAI

Flow Control$94.8M35%
Capital$83.2M31%
Material Handling Systems$70.3M26%
Transferred Over Time$17.1M6%
Other$6.1M2%

PTGX
PTGX

Segment breakdown not available.

Related Comparisons